Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study.
Diabetes mellitus
Glycated haemoglobin
Lipopolysaccharides
Short-Form 36
Type 2
Zonulin
Journal
European journal of nutrition
ISSN: 1436-6215
Titre abrégé: Eur J Nutr
Pays: Germany
ID NLM: 100888704
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
12
06
2019
accepted:
04
11
2019
pubmed:
16
11
2019
medline:
24
6
2021
entrez:
16
11
2019
Statut:
ppublish
Résumé
Diabesity, the combination of obesity and type 2 diabetes, is an ever-growing global health burden. Diabesity-associated dysbiosis of the intestinal microbiome has gained attention as a potential driver of disease and, therefore, a possible therapeutic target by means of pro- or prebiotic supplementation. This study tested the effects of a multispecies synbiotic (i.e. a combination of probiotics and prebiotics) on glucose metabolism, gut microbiota, gut permeability, neutrophil function and quality of life in treatment-experienced diabesity patients. A randomized, double-blind, placebo-controlled pilot study with 26 diabesity patients was conducted in which patients received a daily dose of a multispecies probiotic and a prebiotic (or a placebo) for 6 months. There were no changes in glucose metabolism or mixed meal tolerance test responses throughout the study. The analysis of secondary outcomes revealed beneficial effects on hip circumference [- 1 (95% CI - 4; 3) vs +3 (- 1; 8) cm, synbiotics vs. placebo, respectively, p = 0.04], serum zonulin [- 0.04 (- 0.2; 0.1) vs +0.3 (- 0.05; 0.6) ng/ml, p = 0.004)] and the physical role item of the SF36 quality of life assessment [+ 5.4 (- 1.7; 12.5) vs - 5.0 (- 10.1; 0.2) points, p = 0.02] after 3 months of intervention, and lipoprotein (a) [- 2.1 (- 5.7; 1.6) vs +3.4 (- 0.9; 7.9) mg/dl, p = 0.02] after 6 months. There were no significant differences in alpha or beta diversity of the microbiome between groups or time points. Glucose metabolism as the primary outcome was unchanged during the intervention with a multispecies synbiotic in patients with diabesity. Nevertheless, synbiotics improved some symptoms and biomarkers of type 2 diabetes and aspects of quality of life suggesting a potential role as adjuvant tool in the management of diabesity.
Identifiants
pubmed: 31729622
doi: 10.1007/s00394-019-02135-w
pii: 10.1007/s00394-019-02135-w
pmc: PMC7501130
doi:
Substances chimiques
Biomarkers
0
Lipids
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2969-2983Subventions
Organisme : Österreichische Forschungsförderungsgesellschaft
ID : COMET K1 CBmed
Références
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149. https://doi.org/10.1016/j.diabres.2013.11.002
doi: 10.1016/j.diabres.2013.11.002
pubmed: 24630390
Astrup A, Finer N (2000) Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’? Obes Rev 1:57–59
doi: 10.1046/j.1467-789x.2000.00013.x
Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH (2003) The direct medical cost of type 2 diabetes. Diabetes Care 26:2300–2304
doi: 10.2337/diacare.26.8.2300
Trikkalinou A, Papazafiropoulou AK, Melidonis A (2017) Type 2 diabetes and quality of life. World J Diabetes 8:120–129. https://doi.org/10.4239/wjd.v8.i4.120
doi: 10.4239/wjd.v8.i4.120
pubmed: 28465788
pmcid: 5394731
Delzenne NM, Cani PD (2011) Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 11:154–159. https://doi.org/10.1007/s11892-011-0191-1
doi: 10.1007/s11892-011-0191-1
pubmed: 21431853
Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:99–103. https://doi.org/10.1038/nature12198
doi: 10.1038/nature12198
pubmed: 23719380
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60. https://doi.org/10.1038/nature11450
doi: 10.1038/nature11450
pubmed: 23023125
Chambers ES, Morrison DJ, Frost G (2015) Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? Proc Nutr Soc 74:328–336. https://doi.org/10.1017/s0029665114001657
doi: 10.1017/s0029665114001657
pubmed: 25497601
Byrne CS, Chambers ES, Morrison DJ, Frost G (2015) The role of short chain fatty acids in appetite regulation and energy homeostasis (2005). Int J Obes 39:1331–1338. https://doi.org/10.1038/ijo.2015.84
doi: 10.1038/ijo.2015.84
Chen T, Kim CY, Kaur A, Lamothe L, Shaikh M, Keshavarzian A, Hamaker BR (2017) Dietary fibre-based SCFA mixtures promote both protection and repair of intestinal epithelial barrier function in a Caco-2 cell model. Food Funct 8:1166–1173. https://doi.org/10.1039/c6fo01532h
doi: 10.1039/c6fo01532h
pubmed: 28174773
Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, Liu C, Chen YW, Fan JG (2017) Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol 23:60–75. https://doi.org/10.3748/wjg.v23.i1.60
doi: 10.3748/wjg.v23.i1.60
pubmed: 28104981
pmcid: 5221287
Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, Wilson KE, Glover LE, Kominsky DJ, Magnuson A, Weir TL, Ehrentraut SF, Pickel C, Kuhn KA, Lanis JM, Nguyen V, Taylor CT, Colgan SP (2015) Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17:662–671. https://doi.org/10.1016/j.chom.2015.03.005
doi: 10.1016/j.chom.2015.03.005
pubmed: 25865369
pmcid: 4433427
Leonel AJ, Alvarez-Leite JI (2012) Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 15:474–479. https://doi.org/10.1097/MCO.0b013e32835665fa
doi: 10.1097/MCO.0b013e32835665fa
pubmed: 22797568
Zhong HJ, Yuan Y, Xie WR, Chen MH, He XX (2016) Type 2 diabetes mellitus is associated with more serious small intestinal mucosal injuries. PLoS One 11:e0162354. https://doi.org/10.1371/journal.pone.0162354
doi: 10.1371/journal.pone.0162354
pubmed: 27598308
pmcid: 5012602
Mooradian AD, Morley JE, Levine AS, Prigge WF, Gebhard RL (1986) Abnormal intestinal permeability to sugars in diabetes mellitus. Diabetologia 29:221–224
doi: 10.1007/BF00454879
Horton F, Wright J, Smith L, Hinton PJ, Robertson MD (2014) Increased intestinal permeability to oral chromium (51 Cr) -EDTA in human Type 2 diabetes. Diabet Med 31:559–563. https://doi.org/10.1111/dme.12360
doi: 10.1111/dme.12360
pubmed: 24236770
Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, Komiya K, Kawaguchi M, Shimizu T, Ogihara T, Tamura Y, Sakurai Y, Yamamoto R, Mita T, Fujitani Y, Fukuda H, Nomoto K, Takahashi T, Asahara T, Hirose T, Nagata S, Yamashiro Y, Watada H (2014) Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care 37:2343–2350. https://doi.org/10.2337/dc13-2817
doi: 10.2337/dc13-2817
pubmed: 24824547
Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740–E747. https://doi.org/10.1152/ajpendo.00302.2006
doi: 10.1152/ajpendo.00302.2006
pubmed: 17090751
Hawkesworth S, Moore SE, Fulford AJ, Barclay GR, Darboe AA, Mark H, Nyan OA, Prentice AM (2013) Evidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutr Diabetes 3:e83. https://doi.org/10.1038/nutd.2013.24
doi: 10.1038/nutd.2013.24
pubmed: 23978817
pmcid: 3759130
Jayashree B, Bibin YS, Prabhu D, Shanthirani CS, Gokulakrishnan K, Lakshmi BS, Mohan V, Balasubramanyam M (2014) Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 388:203–210. https://doi.org/10.1007/s11010-013-1911-4
doi: 10.1007/s11010-013-1911-4
pubmed: 24347174
Samah S, Ramasamy K, Lim SM, Neoh CF (2016) Probiotics for the management of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 118:172–182. https://doi.org/10.1016/j.diabres.2016.06.014
doi: 10.1016/j.diabres.2016.06.014
pubmed: 27388674
Akbari V, Hendijani F (2016) Effects of probiotic supplementation in patients with type 2 diabetes: systematic review and meta-analysis. Nutr Rev 74:774–784. https://doi.org/10.1093/nutrit/nuw039
doi: 10.1093/nutrit/nuw039
pubmed: 27864537
Sun J, Buys NJ (2016) Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials. Br J Nutr 115:1167–1177. https://doi.org/10.1017/s0007114516000076
doi: 10.1017/s0007114516000076
pubmed: 26899960
Li C, Li X, Han H, Cui H, Peng M, Wang G, Wang Z (2016) Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: a meta-analysis of randomized, controlled trials. Medicine 95:e4088. https://doi.org/10.1097/md.0000000000004088
doi: 10.1097/md.0000000000004088
pubmed: 27368052
pmcid: 4937966
Yao K, Zeng L, He Q, Wang W, Lei J, Zou X (2017) Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: a meta-analysis of 12 randomized controlled trials. Med Sci Monit 23:3044–3053
doi: 10.12659/MSM.902600
Hu YM, Zhou F, Yuan Y, Xu YC (2017) Effects of probiotics supplement in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Med Clin 148:362–370. https://doi.org/10.1016/j.medcli.2016.11.036
doi: 10.1016/j.medcli.2016.11.036
Zhang Q, Wu Y, Fei X (2016) Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Medicina (Kaunas, Lithuania) 52:28–34. https://doi.org/10.1016/j.medici.2015.11.008
doi: 10.1016/j.medici.2015.11.008
Zhao L, Zhang F (2018) Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359:1151–1156. https://doi.org/10.1126/science.aao5774
doi: 10.1126/science.aao5774
pubmed: 29590046
Dehghan P, Pourghassem Gargari B, Asghari Jafar-abadi M (2014) Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 30:418–423. https://doi.org/10.1016/j.nut.2013.09.005
doi: 10.1016/j.nut.2013.09.005
pubmed: 24332524
Gibb RD, McRorie JW Jr, Russell DA, Hasselblad V, D’Alessio DA (2015) Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus. Am J Clin Nutr 102:1604–1614. https://doi.org/10.3945/ajcn.115.106989
doi: 10.3945/ajcn.115.106989
pubmed: 26561625
Bodinham CL, Smith L, Thomas EL, Bell JD, Swann JR, Costabile A, Russell-Jones D, Umpleby AM, Robertson MD (2014) Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocr Connect 3:75–84. https://doi.org/10.1530/EC-14-0036
doi: 10.1530/EC-14-0036
pubmed: 24671124
pmcid: 3987287
Tajabadi-Ebrahimi M, Sharifi N, Farrokhian A, Raygan F, Karamali F, Razzaghi R, Taheri S, Asemi Z (2017) A randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease. Exp Clin Endocrinol Diabetes 125:21–27. https://doi.org/10.1055/s-0042-105441
doi: 10.1055/s-0042-105441
pubmed: 27219886
Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A (2014) Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 33:198–203. https://doi.org/10.1016/j.clnu.2013.05.015
doi: 10.1016/j.clnu.2013.05.015
pubmed: 23786900
Tajadadi-Ebrahimi M, Bahmani F, Shakeri H, Hadaegh H, Hijijafari M, Abedi F, Asemi Z (2014) Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: a double-blind, randomized, controlled clinical trial. Ann Nutr Metab 65:34–41. https://doi.org/10.1159/000365153
doi: 10.1159/000365153
pubmed: 25196301
Tabrizi R, Moosazadeh M, Lankarani KB, Akbari M, Heydari ST, Kolahdooz F, Asemi Z (2018) The effects of synbiotic supplementation on glucose metabolism and lipid profiles in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Probiotics Antimicrob Proteins 10:329–342. https://doi.org/10.1007/s12602-017-9299-1
doi: 10.1007/s12602-017-9299-1
pubmed: 28677046
Szulinska M, Loniewski I, van Hemert S, Sobieska M (2018) Dose-dependent effects of multispecies probiotic supplementation on the lipopolysaccharide (LPS) level and cardiometabolic profile in obese postmenopausal women: a 12-week randomized clinical trial. Nutrients. https://doi.org/10.3390/nu10060773
doi: 10.3390/nu10060773
pubmed: 30400570
pmcid: 6265939
Sabico S, Al-Mashharawi A, Al-Daghri NM, Wani K, Amer OE, Hussain DS, Ahmed Ansari MG, Masoud MS, Alokail MS, McTernan PG (2018) Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: a randomized, double-blind, placebo-controlled trial. Clin Nutr. https://doi.org/10.1016/j.clnu.2018.08.009
doi: 10.1016/j.clnu.2018.08.009
pubmed: 30170781
Haftenberger M, Heuer T, Heidemann C, Kube F, Krems C, Mensink GB (2010) Relative validation of a food frequency questionnaire for national health and nutrition monitoring. Nutr J 9:36. https://doi.org/10.1186/1475-2891-9-36
doi: 10.1186/1475-2891-9-36
pubmed: 20840739
pmcid: 2945984
Tripolt NJ, Aberer F, Url J, Hogenauer C, Schreiber F, Eherer A, Sourij C, Obermayer AM, Stadlbauer V, Svehlikova E, Brunner M, Kojzar H, Pferschy PN, Pieber TR, Sourij H (2019) Impact of Duodeno-Jejunal bypass liner (EndoBarrierTM) implantation on insulin sensitivity in patients with Type 2 Diabetes Mellitus (T2DM): a study protocol for a pilot trial. Diabetes Ther 10:299–309. https://doi.org/10.1007/s13300-018-0540-z
doi: 10.1007/s13300-018-0540-z
pubmed: 30539524
Tripolt NJ, Leber B, Blattl D, Eder M, Wonisch W, Scharnagl H, Stojakovic T, Obermayer-Pietsch B, Wascher TC, Pieber TR, Stadlbauer V, Sourij H (2013) Short communication: effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, beta-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome—a pilot study. J Dairy Sci 96:89–95. https://doi.org/10.3168/jds.2012-5863
doi: 10.3168/jds.2012-5863
pubmed: 23164226
Wareham NJ, Phillips DI, Byrne CD, Hales CN (1995) The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 12:931
doi: 10.1111/j.1464-5491.1995.tb00399.x
Trieb M, Horvath A, Birner-Gruenberger R, Spindelboeck W, Stadlbauer V, Taschler U, Curcic S, Stauber RE, Holzer M, Pasterk L, Heinemann A, Marsche G (2016) Liver disease alters high-density lipoprotein composition, metabolism and function. Biochim Biophys Acta 1861:630–638. https://doi.org/10.1016/j.bbalip.2016.04.013
doi: 10.1016/j.bbalip.2016.04.013
pubmed: 27106140
pmcid: 5542032
McKenna P, Hoffmann C, Minkah N, Aye PP, Lackner A, Liu Z, Lozupone CA, Hamady M, Knight R, Bushman FD (2008) The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog 4:e20. https://doi.org/10.1371/journal.ppat.0040020
doi: 10.1371/journal.ppat.0040020
pubmed: 18248093
pmcid: 2222957
Stadlbauer V, Horvath A, Ribitsch W, Schmerbock B, Schilcher G, Lemesch S, Stiegler P, Rosenkranz AR, Fickert P, Leber B (2017) Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis. Sci Rep 7:15601. https://doi.org/10.1038/s41598-017-15650-9
doi: 10.1038/s41598-017-15650-9
pubmed: 29142271
pmcid: 5688134
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335–336. https://doi.org/10.1038/nmeth.f.303
doi: 10.1038/nmeth.f.303
pubmed: 3156573
pmcid: 3156573
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP (2016) DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods 13:581–583. https://doi.org/10.1038/nmeth.3869
doi: 10.1038/nmeth.3869
pubmed: 4927377
pmcid: 4927377
Horvath A, Leber B, Schmerboeck B, Tawdrous M, Zettel G, Hartl A, Madl T, Stryeck S, Fuchs D, Lemesch S, Douschan P, Krones E, Spindelboeck W, Durchschein F, Rainer F, Zollner G, Stauber RE, Fickert P, Stiegler P, Stadlbauer V (2016) Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Aliment Pharmacol Ther. https://doi.org/10.1111/apt.13788
doi: 10.1111/apt.13788
pubmed: 27593544
pmcid: 5053220
Stadlbauer V, Horvath A, Komarova I, Schmerboeck B, Feldbacher N, Klymiuk I, Durdevic M, Rainer F, Blesl A, Stiegler P, Leber B (2019) Dysbiosis in early sepsis can be modulated by a multispecies probiotic: a randomised controlled pilot trial. Benef Microbes 10:265–278. https://doi.org/10.3920/bm2018.0067
doi: 10.3920/bm2018.0067
pubmed: 30694100
Eypasch E, Wood-Dauphinee S, Williams JI, Ure B, Neugebauer E, Troidl H (1993) The gastrointestinal quality of life index. A clinical index for measuring patient status in gastroenterologic surgery. Der Chirurg Zeitschrift fur alle Gebiete der operativen Medizen 64:264–274
pubmed: 8482141
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483
doi: 10.1097/00005650-199206000-00002
Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmulling C, Neugebauer E, Troidl H (1995) Gastrointestinal quality of life index: development, validation and application of a new instrument. Br J Surg 82:216–222
doi: 10.1002/bjs.1800820229
Stenman LK, Lehtinen MJ, Meland N, Christensen JE, Yeung N, Saarinen MT, Courtney M, Burcelin R, Lahdeaho ML, Linros J, Apter D, Scheinin M, Kloster Smerud H, Rissanen A, Lahtinen S (2016) Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults-randomized controlled trial. EBioMedicine 13:190–200. https://doi.org/10.1016/j.ebiom.2016.10.036
doi: 10.1016/j.ebiom.2016.10.036
pubmed: 27810310
pmcid: 5264483
Sabico S, Al-Mashharawi A, Al-Daghri NM, Yakout S, Alnaami AM, Alokail MS, McTernan PG (2017) Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naive T2DM patients: a randomized clinical trial. J Transl Med 15:249. https://doi.org/10.1186/s12967-017-1354-x
doi: 10.1186/s12967-017-1354-x
pubmed: 29228964
pmcid: 5725828
Zhang Q, Wu Y, Fei X (2015) Effect of probiotics on body weight and body-mass index: a systematic review and meta-analysis of randomized, controlled trials. Int J Food Sci Nutr 67:571–580. https://doi.org/10.1080/09637486.2016.1181156
doi: 10.1080/09637486.2016.1181156
pubmed: 27149163
Crovesy L, Ostrowski M, Ferreira D, Rosado EL, Soares-Mota M (2017) Effect of Lactobacillus on body weight and body fat in overweight subjects: a systematic review of randomized controlled clinical trials (2005). Int J Obes 41:1607–1614. https://doi.org/10.1038/ijo.2017.161
doi: 10.1038/ijo.2017.161
Solga SF, Buckley G, Clark JM, Horska A, Diehl AM (2008) The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 42:1117–1119. https://doi.org/10.1097/MCG.0b013e31816d920c
doi: 10.1097/MCG.0b013e31816d920c
pubmed: 18936646
pmcid: 4539951
Jones RB, Alderete TL, Martin AA, Geary BA, Hwang DH, Palmer SL, Goran MI (2018) Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial. Pediatric Obes 13:705–714. https://doi.org/10.1111/ijpo.12273
doi: 10.1111/ijpo.12273
Hemert SO, Ormel G (2014) Influence of the multispecies probiotic Ecologic
doi: 10.4236/fns.2014.518187
Fasano A (2012) Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol 10:1096–1100. https://doi.org/10.1016/j.cgh.2012.08.012
doi: 10.1016/j.cgh.2012.08.012
pubmed: 22902773
pmcid: 3458511
Sturgeon C, Lan J, Fasano A (2017) Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model. Ann N Y Acad Sci 1397:130–142. https://doi.org/10.1111/nyas.13343
doi: 10.1111/nyas.13343
pubmed: 28423466
pmcid: 5479715
Lamprecht M, Bogner S, Schippinger G, Steinbauer K, Fankhauser F, Hallstroem S, Schuetz B, Greilberger JF (2012) Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr 9:45. https://doi.org/10.1186/1550-2783-9-45
doi: 10.1186/1550-2783-9-45
pubmed: 22992437
pmcid: 3465223
Polonsky WH, Henry RR (2016) Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 10:1299–1307. https://doi.org/10.2147/ppa.s106821
doi: 10.2147/ppa.s106821
pubmed: 27524885
pmcid: 4966497
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772. https://doi.org/10.2337/db06-1491
doi: 10.2337/db06-1491
pubmed: 17456850
pmcid: 17456850
Gomes JMG, Costa JA, Alfenas RCG (2017) Metabolic endotoxemia and diabetes mellitus: a systematic review. Metabolism 68:133–144. https://doi.org/10.1016/j.metabol.2016.12.009
doi: 10.1016/j.metabol.2016.12.009
pubmed: 28183445
Leber B, Mayrhauser U, Rybczynski M, Stadlbauer V (2009) Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr 121:732–744. https://doi.org/10.1007/s00508-009-1288-2
doi: 10.1007/s00508-009-1288-2
pubmed: 20047110
Richard C, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ (2017) Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. BMJ Open Diabetes Res Care 5:e000379. https://doi.org/10.1136/bmjdrc-2016-000379
doi: 10.1136/bmjdrc-2016-000379
pubmed: 28761653
pmcid: 5530252
Kuwabara WMT, Yokota CNF, Curi R, Alba-Loureiro TC (2018) Obesity and type 2 diabetes mellitus induce lipopolysaccharide tolerance in rat neutrophils. Sci Rep 8:17534. https://doi.org/10.1038/s41598-018-35809-2
doi: 10.1038/s41598-018-35809-2
pubmed: 30510205
pmcid: 6277411
Frydrych LM, Bian G, O’Lone DE, Ward PA, Delano MJ (2018) Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. J Leukoc Biol 104:525–534. https://doi.org/10.1002/jlb.5vmr0118-021rr
doi: 10.1002/jlb.5vmr0118-021rr
pubmed: 30066958
Sousa KH, Williamson A (2003) Symptom status and health-related quality of life: clinical relevance. J Adv Nurs 42:571–577
doi: 10.1046/j.1365-2648.2003.02660.x
Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH (2001) Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 12:2797–2806
pubmed: 11729250
Guglielmetti S, Mora D, Gschwender M, Popp K (2011) Randomised clinical trial: bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life–a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33:1123–1132. https://doi.org/10.1111/j.1365-2036.2011.04633.x
doi: 10.1111/j.1365-2036.2011.04633.x
pubmed: 21418261
Lorenzo-Zuniga V, Llop E, Suarez C, Alvarez B, Abreu L, Espadaler J, Serra J (2014) I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol 20:8709–8716. https://doi.org/10.3748/wjg.v20.i26.8709
doi: 10.3748/wjg.v20.i26.8709
pubmed: 25024629
pmcid: 4093724
Dennis-Wall JC, Culpepper T (2017) Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial. Am J Clin Nutr 105:758–767. https://doi.org/10.3945/ajcn.116.140012
doi: 10.3945/ajcn.116.140012
pubmed: 28228426
Theodoropoulos GE, Memos NA, Peitsidou K, Karantanos T, Spyropoulos BG, Zografos G (2016) Synbiotics and gastrointestinal function-related quality of life after elective colorectal cancer resection. Ann Gastroenterol 29:56–62
pubmed: 26752951
pmcid: 4700848
Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ, Gross JL, Ribeiro JP, Schaan BD (2011) Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 305:1790–1799. https://doi.org/10.1001/jama.2011.576
doi: 10.1001/jama.2011.576
pubmed: 21540423